Inviragen's Hand, Foot and Mouth Disease vaccine generates immune responses in 100% of study participants
In the clinical study, healthy adults received two immunizations each of either a high- or low-dose formulation of INV21. Study participants were monitored for safety and for immune response after each administration. Antibodies that neutralize the EV71 virus were measured in individuals who received both doses of the vaccine. One hundred percent of individuals who received the vaccine had significantly increased EV71 immune responses after immunization, which may signify protection against infection. Further, INV21 was safe and well tolerated in this population. Inviragen expects to present complete safety and immunogenicity data at an appropriate infectious disease meeting in 2012.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.